IQVIA (NYSE: IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence, was named No. 1 in its category on the 2025 Fortune^® World’s Most Admired Companies^™ list. This is the fourth year in a row IQVIA has earned first place in the Health Care: Pharmacy and Other Services category, and the eighth consecutive year it has appeared on the list. Notably, IQVIA earned first place in its category on four key attributes — innovation, global competitiveness, people management and use of corporate assets.

“We are deeply honored to be recognized for the fourth year in a row as number one on the World’s Most Admired Companies list for our category, and to be named to the list for the eighth consecutive year,” said IQVIA Chairman and CEO Ari Bousbib. “This distinction reflects the dedication and impact our employees have in advancing our mission to accelerate innovation for a healthier world. Their commitment and deep expertise drive innovative medical treatments that enhance patient outcomes globally.”

The Fortune^® World's Most Admired Companies^™ list is the definitive report card on corporate reputations. Since 1997, Fortune^® has identified, selected and ranked the World’s Most Admired Companies^™, identifying the business practices that make these companies highly regarded among their peers.

Most Admired Company survey methodology

The annual survey, conducted by Fortune^® and Korn Ferry, a global organizational consulting firm, is given to top executives, directors and financial analysts, to identify the companies that enjoy the strongest reputations within their industries and across industries.

Fortune^® and Korn Ferry analyzed 650 companies and surveyed more than 3,300 executives to measure reputation based on nine different attributes, including each firm’s effectiveness in conducting business globally, its ability to attract, develop, and keep talent, its value as a long-term investment, its innovativeness, its wise use of corporate assets, and its responsibility to the community and environment.

About IQVIA

IQVIA (NYSE: IQV) is a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries. IQVIA’s portfolio of solutions are powered by IQVIA Connected Intelligence^™ to deliver actionable insights and services built on high-quality health data, Healthcare-grade AI^™, advanced analytics, the latest technologies and extensive domain expertise. IQVIA is committed to using AI responsibly, ensuring that its AI-powered capabilities are grounded in privacy, regulatory compliance, and patient safety. With approximately 88,000 employees in over 100 countries, including experts in healthcare, life sciences, data science, technology and operational excellence, IQVIA is dedicated to accelerating the development and commercialization of innovative medical treatments to help improve patient outcomes and population health worldwide.

IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy-enhancing technologies and safeguards to protect individual privacy while generating and analyzing information on a scale that helps healthcare stakeholders identify disease patterns and correlate with the precise treatment path and therapy needed for better outcomes. IQVIA’s insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors and scientific advances, in an effort to advance their path toward cures. To learn more, visit www.iqvia.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250204874891/en/